A lot of health centres are witnessing an increasing amount of people with asbestos cancer. This presents pathologists involved in making the diagnosis with a number of problems, which can be broken up into those encountered in making the distinction between cancer of the mesothelium and benign changes and those discovered in differentiating cancer of the mesothelium from different sorts of e-cadherin and tissue tumors that connect. IHC performs a major role in making the diagnosis, nevertheless it must be taken into consideration with due regard to the scientific setting and radiological characteristics, and with a knowledge of the broad morphological variations existing in malignant mesothelioma.

Cancer of the mesothelium is a cancer affecting the serosal cavities, an anatomical area that also gets affected frequently by mets, predominantly from primary carcinomas of the lung, breast, and ovary. Progression in immunohistochemistry have caused an improvement in diagnostic sensitivity and between metastatic adenocarcinoma and {malignant mesothelioma regarding cytological and histological material. Recently, the researchers employed high throughput technology to the identification of new markers that could help in being able to tell the difference between cancer of the mesothelium from ovarian and peritoneal serous carcinoma, tumors cells that contain closely related histogenesis and antigenic profile. Together with the better tools available for cancer of the serosa diagnosis, understanding the biology of cancer of the mesothelium has accumulate lately.